Wednesday, 14 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 17, 2026

This Will Be McDonald’s Stock Price Next Year

View original at finance.yahoo.com
This Will Be McDonald’s Stock Price Next Year Quick Read McDonald’s (MCD) achieved Q4 2025 revenue of $7B (up 9.7% year-over-year) and EPS of $3.12, beating estimates, while its loyalty platform scaled to 210 million active users generating approximately $37B in annual sales and driving 6.8% U.S…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The risk-reward tilts constructively for patient investors based on comp sales acceleration, loyalty program scaling to $37 billion in annual sales, and continued restaurant expansion in 2026

    60% confidence

  • McDonald's executed a V-shaped recovery through 2025, its loyalty platform is scaling rapidly, and valuation remains reasonable for a franchise-dominant, cash-generating business of this quality

    60% confidence

  • 24/7 Wall St. recommendation is buy with a 90% confidence level

    60% confidence

  • McDonald's plans 2,600 new restaurant openings globally in 2026 to drive 2.5% systemwide sales growth

    60% confidence

  • Loyalty program is approaching 250 million users

    60% confidence

  • McDonald's stock price target is $342, implying 9.7% upside over the next 12 months

    60% confidence

Data points we hold from this source

McDonald's Corporation · stock return ytd0.77 percent
McDonald's Corporation · stock return 1y0.28 percent
McDonald's Corporation · comparable sales growth global5.7 percent
McDonald's Corporation · eps3.12 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com